The best results are obtained by means of a rational combination of chemotherapy and X-ray therapy. We begin the treatment with chemotherapy and then, if necessary, follow it up with X-ray therapy alone, in those cases where the nodules have not completely regressed.
Along with this work we conducted a study of a series of homologues and analogues of Embichin with the aim of finding those compounds which would be the best tolerated and have least depressive action upon bone-marrow haemopoiesis. At first the compounds in which two valencies of nitrogen were occupied by two chloroethyl groups and the third by ethyl, isopropyl, butyl or 2-chloropropyl were synthesised and studied. (The last compound was designated as Embichin No. 7.) 2-Chloroethyl-2-chloropropylmethylamine (designated as Embichin No. 11) and the di-and tri-2-chloropropylamines were also studied.
It became clear that among these compounds, Embichin No. 7 (at first studied experimentally by S. A. Papojan) and Embichin No. 11 (studied by G. L. Zhdanov, Z. P. Sofyina and SH. M. Timerbulatova) were the more effective.
Embichin No. 7, i.e. 2-chloropropyl-di(2-chloroethyl)amine hydrochloride subsequently found practical application. Its action on the animal and human bone marrow is not so severe as on the lymphoid organs. It is much better tolerated by the patients (especially when dissolved in Ringer's solution) possessing a less pronounced side effect upon the gastro-intestinal tract than Embichin.
This new drug, called Novoembichin, has been used in the medical institutions in the U.S.S.R. since 1952, to whom it is supplied by the chemopharmaceutical industry. Clinically, Novoembichin has replaced Embichin since it possessed all the therapeutic properties of Embichin, whilst exerting milder effect upon the bone marrow and very seldom causing vomiting in patients.
The single dose of Novoembichin is higher than that of Embichin. For Hodgkin's disease it is from 9 to 10 mg. for adults; for lymphatic leukemia it is 8 mg., for myelogenous leukemia it is 10 mg. The method of application is the same as that of Embichin, the drug being injected intravenously in 20 ml. of Ringer's solution three times a week. The total course is from 8 to 16 injections.
The need for a therapeutic drug possessing the same activity as Embichin, yet which could be used orally, led us to study the compounds of the aromatic series which are practically insoluble in water. The British investigators Haddow, Kon and Ross (1948) independently followed a similar path. However, we selected the derivative of aniline rather than of naphthylamine. This drug, i.e. N: N-di-(2-chloroethyl) aniline hydrochloride, called Lymphochin, has been studied in detail by animal experiments in the laboratory of the Department of Experimental Chemotherapy of the Institute of Experimental Pathology and Therapy of Cancer, Academy of Medical Sciences, U.S.S.R. (Moscow), by my co-workers A. Y. Krashilina and V. P. Konoplev. We have also studied the corresponding bromoderivative (I. G. Spasskaya).
These compounds when administered orally in daily doses of 5 mg./kg. produced changes in the haemopoietic system of rabbits without injuring the mucous membrane of the gastro-intestinal tract. These changes closely resembled those caused by Novoembichin, but the effect upon the lymphatic system was greater. The crossing of the curves of leucocytes in the blood-the decrease in the number of leucocytes and the increase of pseudoeosinophiles (in absolute figures)-was observed in some animals (Fig. 3) . Lymphochin used at the same dose level did -not exert any harmful effect upon the renal function (E. A. Eard).
These findings enabled us to proceed with the clinical investigations of Lymphochin in the treatment of Hodgkin's disease, which was carried out by G. V. Kruglova, in the clinic of the same Institute.
It became evident that when administered orally in daily doses of 04 g., Lymphochin seldom caused vomiting or nausea in patients and some tolerated it well. According to our findings, as distinct from those of the British investigators (Haddow, Kon and Ross, 1948) , Lymphochin in the doses mentioned above did not induce a marked depression of the bone marrow. Nevertheless, its effect in Hodgkin's disease appeared to be less than that of Embichin and Novoembichin, and its clinical application was dropped, in favour of new drugs which were then being produced. The above mentioned drugs are used exclusively for the treatment of diseases of the haemopoietic system, such as Hodgkin's disease, chronic leukemia, polycythemia and also for some malignant tumours of lymphoid organs, particularly lymphosarcomas and undifferentiated tumours of the lymphatic apparatus of the throat. The successful treatment of the latter condition was carried out by Professor N. A. Karpov and J. N. Smirnova in Leningiad.
The palliative effect of treating bronchogenic carcinoma patients with Embichin was reported in the literature (Boyland, Clegg, Koller, Rhoden and Warwick, 1948) . We also observed it but in our opinion it is of no great practical significance. We have found that the use of Embichin or Novoembichin leads to the regression of breast cancer metastases in cervical and axillary lymphatic nodules (Larionov, Kholdin and Litvinova, 1953) . We followed up a few patients for three years after such treatment and they had no relapses whatsoever. In one patient the regression . The principle of this work was to attempt to increase the anti-tumour properties of the chloroethylamines by adding them as active chemical groups to biologically significant compounds or their components.
From a consideration, particularly of the intensive synthesis of protein and nucleic acid in tumours and also their intensive tissue metabolism in general, some essential amino acids, especiallyphenylalanine, were chosen as such biologically significant compounds. Since heterocycles are the constituents of nucleic acids, of some coferments and vitamins, compounds such as pyrimidine, purine, pyridine, thiazole, benzimidazole, were also selected for preparation of the 2-chloroethylamino derivatives. It was assumed that amino acids and possibly the natural heterocycles might serve as " conductors " assisting the transport of chloroethylamine groups into tumour tissues. Another possibility not to be excluded was that the 2-chloroethylamino-derivatives of the natural compounds might to some extent play the role of antimetabolites in the intensive protein and nucleic acid metabolism of tumour tissues. The synthesis of the chloroethylamino-derivative of pyridoxine was achieved by Stock and his collaborators (Stock et al. 1951 ), but clinical trials were stopped because of the depressant action this drug had on haemopoiesis.
The studyof theactivityof thedi(2-chloroethyl)amino-derivativesof pyrimidine, pyridine, thiazole, benzimidazole and phenylalanine showed that they actually possessed greater anti-tumour activity than Embichin. Different susbtances were tested against sarcoma 45 and M-1 of rats and against a number of transplantable mouse tumours. The aim of these tests was to establish the comparative efficiency of these drugs.
Whilst the inhibition of Sarcoma 45 by Embichin never exceeded 20 per cent, the inhibition caused by the chloroethylamino-derivatives of the above mentioned heterocycles and amino acids was from 60 to 100 per cent, and even more striking, these drugs caused the regression of some or all tumours. It should be noted that the administering of the drugs began when the tumours had already developed and could be measured and weighed.
The comparative studies showed that 2,6-dihydroxy-4-methyl-5-di-(2-chloroethyl)aminopyrimidine (the drug called Dopan), synthesized by V. G. Nemetz and investigated by our assistant G. N. Platonova had the strongest anti-tumour action out of all the investigated heterocyclic derivatives. The drug does not dissolve well in water and is administered orally.
In daily therapeutic doses of 0-3 mg./kg. Dopan causes the gradual regression of tumours (Sarcoma 45) weighing 1-4 g. (i.e. from 1 to 4 per cent of the body weight) in from 90 to 100 per cent of rats (Fig. 4, 5, 6 ).
Dopan has a strong anti-tumour action and at the same time depresses haemopoiesis, especially in the bone marrow. Thus, the administration of the drug to rabbits in daily doses of 0 3 mg./kg. decreases the number of leucocytes in the blood by the seventh or eighth day to 3-4000/c.mm.; this decrease takes place chiefly because of the fall in pseudoeosinophiles.
The clinical trials of Dopan carried out recently at the Institute have already shown that the drug has a marked therapeutic effect in Hodgkin's disease, myelogenic leukemia and reticulo-sarcoma. The drug is administered orally in a dose of 8 to 10 mg. twice weekly. It has almost no side effects upon the gastro-intestinal tract. Its action upon haemopoiesis closely resembles that of Embichin.
We have already reported the biological studies of sarcolysine, DL-p-di(2-chloroethyl)aminophenylalanine, (Larionov et al., 1955) . This drug which was synthesised independently by Bergel and Stock (1954) The drug was injected intravenously in saline solution in doses of from 50 to 25 mg. once weekly in total of from 4 to 6 times under blood count control. The drug is also effective when administered orally in tablets. The metastases of seminomas into retroperitoneal and peripheral lymph nodes even of large size regressed after 3 to 5 injections of sarcolysine. Two patients (one with cured metastasis of seminomas on the neck and one with retroperitoneal lymph nodules) were followed up by us for 11 and 8 months respectively and have had no relapse.
With incomplete regression, especially in reticulosarcoma, relapses were observed. With correct dosage the depression of haemopoiesis is moderate and normal blood content is re-established in from 3 to 4 weeks. With the dosage higher than optimal some patients showed a sharp depression of haemopoiesis down to agranulocytosis accompanied by high fever. Clinical studies are still under way.
Thus, systematic work on synthesis and application of chloroethylamine derivatives of natural heterocycles and amino acids has led to the creation of new therapeutic drugs of anti-tumour action. It is probable that further investigations in this field can lead to further successes. . . . . VOl-X, NO. 1.
